For compounded medications, pharmacists use a Beyond-Use Date (BUD) rather than a traditional manufacturers expiration date
The landmark SELECT trial significantly expanded the therapeutic paradigm by demonstrating a 20% relative risk reduction in three-point major adverse cardiovascular events (MACEs) with semaglutide 2.4 mg in 17,604 patients with obesity but without diabetes, leading to FDA approval for cardiovascular risk reduction in March 2024 [82]
These compounds are generated by activated microglia the CNSs primary immune cells and astrocytes, as well as by neurovascular units consisting of neurons, pericytes, and endothelial cells (38)
After that, the dose increases to 0.5 mg weekly
Women Who Should Avoid or Use Caution with PT-141 Certain medical conditions may make PT-141 inappropriate or require careful monitoring
Eligibility can vary depending on the specific medication